| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
ALLEGAN, Mich.—Perrigo Co. announcedDec. 28 that it had signed a definitive merger agreement and had completedthe acquisition of Cobrek Pharmaceuticals Inc., aprivately-held, Chicago-based drug development company, forapproximately $45 million on a cash-free and debt-free basis.

In May 2008, Perrigo acquired an 18.5-percentminority stake in Cobrek in conjunction with entering into a productdevelopment collaborative partnership agreement with the companyfocused on foam dosage form generic pharmaceutical products.
 
To date,the partnership has successfully yielded two commercializedfoam-based products and two additional U.S. Food and DrugAdministration (FDA) approved foam-based products awaiting datecertain launches in Perrigo's fiscal year 2013. Cobrek primarilyderives its earnings stream from profit shares on products partneredwith Perrigo, who is responsible for all commercial activities underthe existing collaboration agreement. As part of the transaction,Cobrek will forgo any profit share payments earned during Perrigo'sfiscal second quarter 2013.

"We continue to market the only genericfoam products in the U.S. and expect to launch two additionalproducts generic versions of Luxiq (betamethasone valerate) Foamand Olux-E (clobetasol propionate) Foam 0.05% during this fiscalyear, which is a testament to the challenges of this dosage form andsuccess of our partnership with Cobrek," said Joseph C. Papa, Perrigo's chairman, president and CEO. "The partnership also boastsan additional Abbreviated New Drug Application (ANDA) on file for apromising topical generic product. This acquisition allows us tocapture the full economics going forward on our portfolio ofprescription foams as well as maintain control over futuredevelopment activities in this important category of extended topicalproducts. Acquiring the remaining stake of Cobrek not already ownedis the logical next step in this relationship and will allow us tocontinue to bring quality, affordable healthcare to our consumers andcustomers."

SOURCE: Perrigo Co. news release
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
A starry night sky reflected over calm water, symbolizing the discovery of hidden patterns in complex systems.

Technology Guide: Spatial biology techniques

Discover essential strategies and expert insights to navigate the expanding world of spatial biology.
Red tumor cells are shown against a teal backdrop showing attachment to tissue.

Decoding the tumor microenvironment with immune profiling

Integrating multiplexed immunohistochemistry with spatial analysis offers a practical way to uncover tumor-immune dynamics.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue